GLP1R and inflammatory bowel disease: In meta-analysis, the pooled HR for surgery was in favor of GLP1-RA therapy compared to non-GLP1-RA therapy (logHR: 0.61, 95% CI: 0.44-0.84, I2 = 0%, P = 0.003) in patients with IBD (Figure 3).